Clinical description
Akathisia is a state of motor restlessness commonly seen after the administration of antipsychotic drugs. It is characterized by a subjective feeling of tension and inability to tolerate inactivity which gives rise to restless movement. When mild this is seen as continuous shuffling or tapping movement of the feet while sitting, and persistent shifting of weight and rocking of the trunk while standing. In more severe cases the person is unable to sit, stand or lie still, and paces or runs incessantly in extreme distress. The latter was referred to by earlier writers as 'paradoxical behavioural reactions' and 'turbulent reactions' (Sarwer-Foner 1961) .
Historically the psychopathology of akathisia has been a matter of debate (Marsden et al. 1975 , Van Putten 1975 . It was first described in 1903 by Hastovec, who felt the disorder was hysterical in nature. Bing (1939) described akathisia as a psychosis, 'characterised by a morbid fear of sitting down', but later thought it might be a way of overcoming the muscular rigidity of Parkinson's disease. Oppenheim (1911) considered akathisia to be a neurosis, 'usually a form of phobia', and Wilson (1940) designated it a hysterical phenomenon although he described the syndrome in association with Parkinson's disease. Akathisia was often seen in postencephalitic Parkinson's disease and when arising as an early symptom was frequently diagnosed as being hysterical. Its association with postencephalitic and drug-induced parkinsonism led people to consider it a disorder of the extrapyramidial system.
The subjective experience of akathisia is closely akin to anxiety, which can cause it to be mistaken for an exacerbation of the original mental illness. Hodge (1959) observed that akathisia 'May appear like an anxiety state in which real anxiety can be neither recognized nor verbalized'. Raskin (1972) said that some patients were unable to distinguish between anxiety and the restlessness of akathisia and he advised clinicians to watch for symptoms such as uneasiness, hyperactivity, pacing and vague complaints about medication. He felt it was frequently responsible for apparent deterioration in patients after starting antipsychotic medication. Van Putten (1975) cited akathisia as a common cause for discontinuing neuroleptic medication, particularly as it is poorly tolerated by paranoid schizophrenics whose worries of bodily interference are seemingly confirmed. Kalinowsky (1958) said akathisia could be 'more difficult to endure than any of the symptoms for which the patient was originally treated'.
Van Putten (1975) described varying presentations of akathisia associated with strong feelings of fright, terror, anger, rage and vague somatic complaints. In one case the restlessness of akathisia was experienced as sexual torment, the patient describing 'cravings' which she had never known before and could not satisfy. Kumar (1979) described the difficulty psychotic or mentally retarded individuals may suffer in verbalizing their subjective experience of akathisia which may present as aggressive or uncontrollable behaviour disturbance.
Incidence Ayd (1961) studied the incidence of extrapyramidal side effects in 3775 patients receiving a variety of antipsychotic drugs in normal therapeutic doses, and found that 21.2% developed akathisia. Frehan (1958) Van Putten (1975) reported an incidence of 45%. His patients were continuously monitored by staff trained to recognize signs and also subjective feelings of restlessness which were reversed by administration of biperiden but not placebo. Akathisia was the most frequent side effect, and 59% of patients with akathisia also experienced other extrapyramidal phenomena including akinesia, pseudoparkinsonism, tremor and dystonia. Braude et al. (1983) diagnosed akathisia in 27 of 104 patients taking dopamine blocking medication, the severity ranging from 'mild' where symptoms were predominantly subjective, to 'moderate' where some objective symptoms were present, and 'severe' where patients were unable to sit or lie still. Ayd (1961) found akathisia to be rare in the first 48 hours after starting neuroleptic medication; thereafter the incidence gradually increased, with 50% of cases developing it by one month and 90% by 3 months. Duration of symptoms was variable and they occasionally disappeared spontaneously. Stopping the offending drug usually led to a decrease in symptoms, but some cases persisted unchanged for several months. Schilkrut et al. (1978) noted two distinct peaks in the onset of symptoms of akathisiaat one and 36 weeks after the onset of treatment -which were thought to demonstrate two different populations. This contrasted with the incidence of rigor, which increased to a critical point at the 24th week after which it gradually declined to be completely absent at the 60th week. In the study of Braude et al. (1983) , 85% of patients displayed symptoms within 7 days of reaching the maximum dose of the drug, 3 developed symptoms within 12 hours of receiving the first dose and all had developed symptoms within 14 days of starting the maximum dose.
Reports of drug-induced symptoms should be seen against the background of the older literature in which there was much discussion of the incidence of spontaneous movement disorders in untreated schizophrenic patients. Mannerisms and stereotypes were the most common motor disorders mentioned. According to the original descriptions, these occurred early in the course of the illness and persisted for many years, eventually dominating the person's daily life. Of patients diagnosed as catatonic schizophrenic, 24% demonstrated some features of akathisia such as excessive leg lifting, running, hopping, shuffling, rocking, together with manipulative movements of the hands and arms and movements of the face, mouth and tongue seen in tardive dyskinesia. Kraeplin described choreiform of the face and fingers which he called 'athetoid ataxia'. A similar condition was named 'parrakinesia' by Wernicke, who thought it was akin to chorea. Blueler, however, claimed never to have seen a case of chorea in a schizophrenic. The presence of organic brain disease in some of these patients is a possible explanation, together with the effects of institutionalization (Sarwer-Foner 1961) .
Aetiological factors Pharmacology
Drug-induced akathisia is not confined to the psychiatrically ill. Symptoms have been reported in patients with no psychiatric history given phenothiazine medication preoperatively (Barnes et al. 1982) . Ayd (1961) noted that symptoms of akathisia were significantly more prevalent when drugs with a halogen substitution or a piperazine side chain were used. Kane et al. (1978) found an incidence of extrapyramidal side effects of 26% in patients treated with fluphenazine enanthate compared with 4% of those treated with fluphenazine decanoate.
Some studies of predisposing factors have reported akathisia to be more common in women than men. These are not supported by the recent study of Braude et al. (1983) which found no difference in age or sex between those suffering from akathisia and the rest of the group. Ayd (1961) also found no specific predisposing factors in terms of age or sex, unlike other drug-induced syndromes. Channard (1979) , studying tardive dyskinesia, found an incidence of 31% in chronic schizophrenics treated with neuroleptics. Predisposing factors isolated were being elderly, having a long record of hospitalization, having a poor response to neuroleptics in terms of symptom amelioration and treatment with fluphenazine. He found an inverse relationship between symptoms of tardive dyskinesia and parkinsonism although no such similar relationship with akathisia. This led him to speculate that tremor and akathisia were 'hyperkinetic Parkinsonian symptoms' and were precursors of dyskinesia, the two being expected to coexist; whereas 'hypokinetic Parkinsonian symptoms' of rigidity and akinesia might reduce or mask the expression of dyskinesia and thus the two conditions would not be expected to occur together. Braude et al. (1983) found no relationship between the incidence of akathisia and tardive dyskinesia.
Neurology
Attempts have been made to correlate movement disorders resulting from neuroleptic medication with neurological syndromes. A number of such syndromes have akathisia-like features. One of these is the 'restless leg syndrome', first described by Thomas Willis in the 17th century and more recently by Ekbom (1965) . It is said to consist of a creeping and crawling sensation of the lower leg, usually bilateral and symmetrical, which starts within 5-30 minutes of retiring to bed and causes insomnia. It is associated with poliomyelitis, avitaminosis, diabetes and pregnancy. It differs from akathisia in being restricted to the legs and the latter part of the day.
A similar picture to akathisia is seen in the condition of 'molimina crurum noctura'. Characteristic symptoms are restlessness, creeping sensations, aches, cramps, stretched tendons, jerkings, burnings and numbness of the legs. Other neurological syndromes likened to akathisia include neuralgia paraesthetica and myokinia, a primary disorder of muscle, but none of these is accompanied by the subjective sensation of restlessness which is the most consistent clinical observation in akathisia.
Akathisia is seen only very rarely in idiopathic Parkinson's disease but was seen relatively commonly in patients suffering from postencephalitic parkinsonism. Like oculogyric crises, it emphasizes similarities between the drug-induced syndrome and that seen after encephalitis lethargica.
Pathophysiology
The neurochemical basis for akathisia is uncertain. Like parkinsonism, it is seen after treatment with phenothiazines, butyrophenones and reserpine (0.5-8%). Amphetamines have been reported to ameliorate symptoms of akathisia and there is no response to physostigmine. It is a paradox that drugs given partly for their calming effect should produce the syndrome of akathisia (Marsden & Jenner 1980) . Recently a number of mechanisms have been put forward as possible explanations.
Neuroleptic drugs block postsynaptic dopamine receptors and are thought to cause a compensatory increase in the rate of dopamine turnover (Carlsson 1977) . It has been suggested that dopaminergic autoreceptors exist in the presynaptic nerve terminals which, when activated, decrease dopamine synthesis, thus acting to reduce levels of dopamine. If these receptors were selectively blocked, a paradoxical increase in dopamine synthesis would occur. This has been the suggested mechanism of dopamine agonists, such as apomorphine, which inhibit motor activity in animals at low level but stimulate it at high levels (DiChiara et al. 1976 , Strombom 1977 . Selective presynaptic dopamine receptor blockade has been proposed as the origin of drug-induced akathisia, but a number of objections can be raised. One is that reserpine and tetrabenzine can cause akathasia, despite their action being to deplete dopamine stores and therefore lower levels of dopamine in the brain. Secondly, akathisia coexists with parkinsonism. The pathophysiology of parkinsonism is the opposite to that proposed above, being a relative depletion of dopamine levels in the nigrostriatal system. Unless one considers receptor blockade in dopamine containing areas outside the corpus striatum, it is difficult to envisage the two conditions as coexisting (Marsden et al. 1975) .
In 1973 Thierry et al. were able to demonstrate for the first time dopaminergic terminals in the rat cerebral cortex. These had to be shown as independent of noradrenergic terminals so that dopamine was not just an intermediary metabolite. Ascending noradrenergic pathways were destroyed by injecting a superior cerebellar peduncle on both sides. Synthesis of noradrenaline from tyrosine was abolished, but that of dopamine could be demonstrated in specimens after the lesion. The cell bodies of these dopaminergic neurones were later found to be situated in the mid-brain, and this is now referred to as the mesocortical dopaminergic system as compared with the mesolimbic system which serves the corpus striatum.
Evidence to link drug-induced akathisia with the mesocortical dopaminergic system comes from the work of Tassin et al. (1978) . Bilateral lesions of the ventral tegmental area (VTA) in rats induced a behavioural syndrome characterized by permanent locomotor hyperactivity and reduction in attention capacity. This could be seen as a rodent equivalent of akathisia. The VTA contains cell bodies of the mesocortical dopaminergic system and also 5-HT fibres originating in the raphe nucleus and innervating the forebrain. Tassin measured levels of amines in the brain following lesions of the VTA and correlated them with incidence of the VTA behavioural syndrome. He found no correlation between levels of 5-HT and induced locomotor behaviour but did find significant correlation between increasing locomotor activity and decreased dopamine content in the frontal cortex after the VTA lesion. He also found a less significant correlation between locomotor behaviour and dopamine levels in the nucleus accumbens, a structure innervated by the mesolimbic dopaminergic system.
It could be proposed from the above that the mesocortical dopaminergic system operates an inhibitory effect on motor activity, and opposed synaptic blockade at this point would have a similar affect to producing a lesion of the VTA releasing motor activity.
Treatment and prognosis
Akathisia has traditionally been treated with anticholinergic medication which anecdotally has been successful. Raskin (1972) recommended the addition of a barbiturate to an anticholinergic drug in the treatment of resistant cases. Gagrat et al. (1978) carried out a double-blind controlled trial comparing intravenous diazepam with diphenhydramine in akathisia. Patients were rated on a three-point scale, one point being awarded for 'subjective inner restlessness', two points for 'objective restlessness' and three points for 'severe objective restlessness'. Ratings were taken at 5 minutes, 15 minutes, 30 minutes and two hours. Both groups achieved considerable but incomplete amelioration of symptoms after 2 hours, and there was no significant difference between the two treatments. Amantadine has been suggested as a therapeutic agent by Ananth et al. (1977) and Greenblatt et al. (1977) . A recent uncontrolled study by Lipinski et al. (1984) reported complete remission in 9 out of 14 patients treated with propranolol and a substantial improvement in the remaining 5. There was no improvement in symptoms of tardive dyskinesia or parkinsonism on this regimen.
Prognosis seems uncertain. The literature suggests that most cases remit in days or weeks after stopping neuroleptic medication. However, some may persist for several months or become permanent.
Conclusion
Akathisia is a common and unpleasant side effect of neuroleptic medication. It has been given relatively little attention by clinicians and those in research, and unfortunately the natural history and response to treatment have not been completely elucidated. Speculation as to its pathophysiology leads to an interesting area of brain research.
